Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.44 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | SGK1 | O00141 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | STK3 | Q13188 | 1/20 | 0.39 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21962027 | 1.00 | LRRK2 (0.44) | LRRK2LIMK2MAPK1SGK1ACACB | |
| SCHEMBL22011264 | 1.00 | LRRK2 (0.44) | LRRK2LIMK2MAPK1SGK1ACACB | |
| SCHEMBL21962025 | 1.00 | LRRK2 (0.44) | LRRK2LIMK2MAPK1SGK1ACACB | |
| SCHEMBL21961980 | 0.90 | MAPK1 (0.47) | LIMK2MAPK1SGK1 | |
| SCHEMBL22011263 | 0.90 | MAPK1 (0.47) | LIMK2MAPK1SGK1 | |
| SCHEMBL21961979 | 0.90 | MAPK1 (0.47) | LIMK2MAPK1SGK1 | |
| SCHEMBL21961967 | 0.89 | MAPK1 (0.50) | MAPK1 | |
| SCHEMBL21961966 | 0.89 | MAPK1 (0.50) | MAPK1 | |
| SCHEMBL21962015 | 0.89 | MAPK1 (0.50) | MAPK1 | |
| SCHEMBL21961963 | 0.84 | MAPK1 (0.40) | LRRK2LIMK2MAPK1SGK1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428416-B2 | ERK inhibitors and uses thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-09-30 | — | — | US | disclosed |
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-01-06 | — | — | US | disclosed |
| EP-3880677-A1 | ERK INHIBITORS AND USES THEREOF | California Institute of Technology (US) | 2021-09-22 | — | — | EP | disclosed |
| CN-113423707-A | ERK inhibitors and uses thereof | 加利福尼亚技术学院 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020102686-A1 | ERK INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002294-A1 | ERK INHIBITORS AND USES THEREOF | MAPKAPK2, MAPK3, MAP4K2 | LRRK2 359/4885LIMK2 314/4885MAPK1 11/4885 |
| US-12428416-B2 | ERK inhibitors and uses thereof | MAPKAPK2, MAPK3, MAP4K2 | LRRK2 359/4885LIMK2 314/4885MAPK1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.